StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Vincristinsulfat

Vincristine Sulfate

HCID 249332
Neue Reaktion
Drucken
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
2068-78-2
Standard-SMILES
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
InChIKey
AQTQHPDCURKLKT-JKDPCDLQSA-N
Summenformel
C46H56N4O10.H2O4S
Durchschnittliche Molmasse
923 g/mol
Monoisotopische Masse
922,36702371

Überblick

Vincristine Sulfate can cause developmental toxicity according to state or federal government labeling requirements.

Namen und Bezeichner

Bevorzugter Name
Vincristine Sulfate
IUPAC
methyl (1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-4-[(13S,15S,17S)-17-ethyl-17-hydroxy-13-methoxycarbonyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-13-yl]-8-formyl-10-hydroxy-5-methoxy-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate;sulfuric acid
Lokaler Name
Vincristinsulfat
Englischer Name
Vincristine sulfate
Summenformel
C46H58N4O14S
Molmasse
923.04

Namen und Synonyme

Vincristine sulfate2068-78-2OnkovinVCR sulfateVincristine sulphateKyocristineVincrisulLilly 37231NovopharmVincristini sulfasLeurocristine sulfateVincaleukoblastine, 22-oxo-, sulfate (1:1) (salt)
Weitere Namen anzeigen
oncovinVCRvincristinVincristin SulfateVinorelbine SulfateVINCRISTINE SULFATE USPVINCRISTINE SULFATE SALT
NSC 67574VincrexLeurocristine, sulfate (1:1) (salt)Vincristine, sulfateLeurocristine, sulfateVincasar PFSNSC67574Vincristine Sulfate PFS

Datenbank-Bezeichner

CAS
2068-78-2
PubChem CID
249332
DTXSID
DTXSID8044331

Eigenschaften

Berechnete Struktureigenschaften

Polarare Oberfläche (TPSA)
254 Ų
H-Brücken-Donoren
5
H-Brücken-Akzeptoren
16
Frei drehbare Bindungen
10
Schwere Atome
65
Formalladung
0
Komplexität
1.830

Experimentelle und physikochemische Eigenschaften

Solubilitygreater than or equal to 10 mg/mL at 75 °F (NTP, 1992)
Human Drugs · 3 Einträge

Breast Feeding; Lactation; Milk, Human; Antineoplastic Agents; Antimitotic Agents

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Melting Point531 °F approximately (NTP, 1992)
Physical DescriptionVincristine sulfate appears as an anticancer drug. White to slightly yellow, amorphous or crystalline powder. Sensitive to light. Odorless. pH (0.1% solution) 3.5 - 4.5. (NTP, 1992)
Collision Cross Section281 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Physikochemische Eigenschaften

Schmelzpunkt
300 °C · 300 °C
Siedepunkt
273 · 273-281 °C
storage temp.
-20 °C · Sealed in dry,Store in freezer, under -20°C
Löslichkeit

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 4 Einträge

Danger

H300 (91.5%): Fatal if swallowed [Danger Acute toxicity, oral]

P203, P264, P270, P280, P301+P316, P318, P321, P330, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 47 reports by companies from 9 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Gefahrenhinweise

Regulatory InformationHazard Traits - Developmental Toxicity
Other Safety InformationIMAP assessments - Vincaleukoblastine, 22-oxo-, sulfate (1:1) (salt): Human health tier I assessment
DOT LabelPoison
Fire HazardsFlash point data for this chemical are not available; however, it is probably combustible. (NTP, 1992)
Health Hazards · 1 Eintrag

SYMPTOMS: The following symptoms of exposure have occurred during intravenous use. Symptoms of exposure include bone marrow depression, peripheral neuropathy, colicky abdominal pain, constipation and alopecia. Other symptoms include neuromuscular and neurological disturbances, gastrointestinal upset and leucopenia. It has caused impaired walking, convulsions, hypertension, inappropriate antidiuretic hormone (ADH) secretion, jaw pain, paresthesias in the fingers and toes, sensory impairment, headache, loss of deep tendon reflexes, parotid gland pain, optic atrophy and blindness. It has also caused acute uric acid nephropathy, myocardial infarction, ocular toxicity (ptosis, other ocular muscle paresis, and 5th and 7th nerve involvement); laryngeal nerve paralysis causing hoarseness or cough, depression of the Achilles tendon reflex, muscle pain, weakness, motor weakness, quadriparesis, numbness and tingling of the fingers and toes, malaise, depression, psychoses, neuromyopathy, peripheral neuritis, adynamic ileus, and permanent central nervous system damage. Exposure may cause paresthesia, foot drop, ataxia, athetosis, thrombocytosis and coma. Exposure may also cause granulocytopenia, thrombocytopenia, hypoplasia of all elements of bone marrow, nausea, vomiting, anorexia, neuritic pain and motor difficulties. Other effects may include cranial nerve neuropathy including optic nerve neuropathy and injury to the retina; cataracts, facial paralysis, diplopia and corneal hypesthesia. It may cause anemia, polyuria, dysuria, fever, tingling and numbness of the extremities, abdominal obstruction, ischemic cardiac toxicity and syndrome of hyponatremia. It may also cause diarrhea, sensory loss, slapping gait, muscle wasting, generalized sensorimotor dysfunction, paralytic ileus, abdominal cramps, rash, oral ulceration, intestinal necrosis and/or perforation, urinary retention due to bladder atony cranial nerve manifestations including isolated paresis and/or paralysis of muscles controlled by cranial motor nerves; pharyngeal pain, bone pain, back pain, limb pain, myalgias, renal or adrenal disease, hypotension, dehydration, azotemia and clinical edema. Effects on the autonomic nervous system have been reported. It may cause irritation of the skin, and congenital malformation in the fetus.

Chemie und Industrie

Pharmakologische Informationen

Metabolism/Metabolites · 1 Eintrag

Hepatic. Cytochrome P450 isoenzymes of the CYP3A subfamily facilitate the metabolism of vincristine. Route of Elimination: The liver is the major excretory organ in humans and animals. 80% of an injected dose of vincristine sulfate is excreted via feces. 10 - 20% is excreted via urine. Half Life: When intravenously injected into cancer patients, a triphasic serum decay patten was observed. The initial, middle, and terminal half-lives are 5 minutes, 2.3 hours, 85 hours respectively. The range of the terminal half-life is humans is 19 - 155 hours.

FDA Pharmacological Classification · 2 Einträge

VINCRISTINE SULFATE

Vinca Alkaloids [CS]; Vinca Alkaloid [EPC]

MeSH Pharmacological Classification · 2 Einträge

Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity.

Agents that interact with TUBULIN to inhibit or promote polymerization of MICROTUBULES.

Verwendung und Herstellung

Uses · 1 Eintrag

Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).

Anwendungen

VerwendenVincristine sulfate, is used as an anticancer agent, microtubule disrupter, Induces apoptosis in human lymphoma cells. Other applications include as a cell cycle arresting, apoptotic inducing alkaloid.

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

Zugehörige Reaktionen

7
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 437029
HRID 437029als Edukt
Reaktionsgleichung von HRID 970265
HRID 970265als Edukt
Reaktionsgleichung von HRID 1295536
HRID 1295536als Edukt
Reaktionsgleichung von HRID 1296337
HRID 1296337als Edukt
Reaktionsgleichung von HRID 1363907
HRID 1363907als Edukt
Reaktionsgleichung von HRID 1788651
HRID 1788651als Edukt
Reaktionsgleichung von HRID 2085903
HRID 2085903als Edukt

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
ChEMBL
CHEMBL501867
EC Number
218-190-0
20 mg/mL · methanol: soluble20mg/mL
Aggregatzustand
lyophilized powder
Farbe
white to off-white
Wasserlöslichkeit
1 g/100 · >=1 g/100 mL at 24 ºC
BRN
3924631 · 3924631
Stabilität
2 years · Stable for 2 years from date of purchase as supplied. Solutions in distilled water may be stored at -20° for up to 3 months.
Major Application
pharmaceutical (small molecule)
InChIKey
AQTQHPDCURKLKT-HSMPTBRCNA-N
SMILES
OS(O)(=O)=O.CC[C@]1(O)CC2CN(CCc3c([nH]c4ccccc34)[C@@](C2)(C(=O)OC)c5cc6c(cc5OC)N(C=O)C7[C@](O)([C@H](OC(C)=O)[C@]8(CC)C=CCN9CC[C@]67C89)C(=O)OC)C1
EPA chemische Informationen
Vincristine sulfate (2068-78-2)
Reactive GroupAlcohols and Polyols
Reactivity ProfileSensitive to hydrolysis, oxidation and heat. Incompatible with strong oxidizing agents. (NTP, 1992).
Air and Water ReactionsVery hygroscopic. Water soluble.
Hazard Classes and CategoriesAcute Tox. 2 (91.5%)

Sicherheit und Schutzausrüstung

Fire FightingFires involving this material can be controlled with a dry chemical, carbon dioxide or Halon extinguisher. A water spray may also be used. (NTP, 1992)
First Aid · 1 Eintrag

EYES: First check the victim for contact lenses and remove if present. Flush victim's eyes with water or normal saline solution for 20 to 30 minutes while simultaneously calling a hospital or poison control center. Do not put any ointments, oils, or medication in the victim's eyes without specific instructions from a physician. IMMEDIATELY transport the victim after flushing eyes to a hospital even if no symptoms (such as redness or irritation) develop.

Nonfire Spill Response · 1 Eintrag

SMALL SPILLS AND LEAKAGE: If you spill this chemical, you should dampen the solid spill material with water, then transfer the dampened material to a suitable container. Use absorbent paper dampened with water to pick up any remaining material. Seal your contaminated clothing and the absorbent paper in a vapor-tight plastic bag for eventual disposal. Wash all contaminated surfaces with a soap and water solution. Do not reenter the contaminated area until the Safety Officer (or other responsible person) has verified that the area has been properly cleaned.

Isolation and EvacuationExcerpt from ERG Guide 151 [Substances - Toxic (Non-Combustible)]:
Personal Protective Equipment (PPE) · 1 Eintrag

RECOMMENDED RESPIRATOR: Where the neat test chemical is weighed and diluted, wear a NIOSH-approved half face respirator equipped with an organic vapor/acid gas cartridge (specific for organic vapors, HCl, acid gas and SO2) with a dust/mist filter. (NTP, 1992)

Toxikologische Informationen

Toxicity Summary · 1 Eintrag

The antitumor activity of Vincristine is thought to be due primarily to inhibition of mitosis at metaphase through its interaction with tubulin. Like other vinca alkaloids, Vincristine may also interfere with: 1) amino acid, cyclic AMP, and glutathione metabolism, 2) calmodulin-dependent Ca<sup>2+</sup>-transport ATPase activity, 3) cellular respiration, and 4) nucleic acid and lipid biosynthesis.

Carcinogen Classification · 6 Einträge

Vincristine sulfate

Group 3: Not classifiable as to its carcinogenicity to humans

Volume 26: (1981) Some Antineoplastic and Immunosuppressive Agents

1987

1987

Vincristine sulfate is not classifiable as to its carcinogenicity to humans (Group 3). Vincristine is part of MOPP, a combination chemotherapy regimen that is carcinogenic to humans (Group 1). (L135)

Drug Induced Liver Injury · 6 Einträge

Drug Induced Liver Injury Rank (DILIrank 2.0)

Vincristine sulfate

vLess-DILI-concern

8

Adverse reactions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
Toxicity DataIVN-RAT LD<sub>50</sub> 1300 mg/kg; IPR-MUS LD<sub>50</sub> 5.2 mg/kg.

Sicherheitsdaten

F
8-10
wgk
3
ridadr
UN 2811 6.1/PG 2
hs_code
29399990
RTECS-Nr.
OH6340000
risk_code
61-36/37/38-63-23/24/25-68-62-25
Toxizität
LD50 intraperitoneal in mouse: 3mg/kg
hazard_code
T
safety_code
22-24/25-53-45-37/39-26-36/37/39-36/37
hazard_class
6.1(a)
packing_group
II
Speicherklasse
6.1A - Combustible acute toxic Cat. 1 and 2very toxic hazardous materials
Hazard Classifications
Acute Tox. 2 OralMuta. 2Repr. 2
SchwefelsureBenzol

Nachgelagerte Produkte

Vindesin